Tag: IN.PACT

VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...

European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT...

Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long...

IN.PACT Admiral DCB shows ‘significant advantage’ over uncoated devices in fempop...

The IN.PACT Admiral drug-coated balloon (DCB) demonstrated a significant advantage in overall survival, amputation-free survival and target-lesion revascularization after femoropopliteal artery treatment through four-year...

Six-month IN.PACT AV Access results show superiority of DCB angioplasty

Just-published six-month results of the IN.PACT AV Access study show that drug-coated balloon (DCB) angioplasty is superior to standard angioplasty for the treatment of...

SVS acknowledges industry partners springing to aid of vascular community

It has recently come to the attention of the Society for Vascular Surgery (SVS) that many of our industry partners are generously donating equipment...

TOBA III clinical trial results published

Intact Vascular has announced the peer-reviewed publication of its Tack optimized balloon angioplasty (TOBA) III 12-month clinical trial results in the Journal of Vascular Surgery. The multi-center, single-arm,...